Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2023-04-03 Regulatory Filings
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(LCB14(HER2-ADC) 관련 마일스톤 기술료 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Legochem Biosciences regarding a milestone payment received from a licensing agreement with Fosun Pharma. It details the financial impact (13.61% of 2022 revenue) and the nature of the transaction. Since it is a specific regulatory disclosure of a material event (major management/business matter) rather than a recurring financial report or a simple announcement of a report's publication, it falls under the general regulatory filing category.
2023-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend status, director appointments, and remuneration limits. This aligns perfectly with the definition of a Declaration of Voting Results (DVA), which reports the official outcomes of shareholder votes at a general meeting.
2023-03-31 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Supervisory Service/Korea Exchange. It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the regulator that does not fit into the more specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2023-03-31 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) which includes detailed agenda items, management reports, and financial information for the upcoming meeting. While it contains financial data, it is not an Annual Report (10-K) or an Interim Report (IR) itself, but rather the proxy materials and meeting notice sent to shareholders to solicit votes and provide information for the AGM. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category, as it serves to inform shareholders and request votes for the meeting.
2023-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from a Korean company (LegoChem Biosciences) titled 'Audit Report Submission' (감사보고서 제출). It provides the auditor's opinion, key financial data (assets, liabilities, equity, profit/loss), and details regarding the audit process. While it contains financial data, it is a formal regulatory announcement of the audit report's submission to the exchange, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2022
2023-03-23 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for the 17th fiscal year (2022) of LegoChem Biosciences, Inc. It contains comprehensive company information, including financial summaries, capital changes, shareholding structure, and corporate governance details. In the context of Korean corporate filings, the '사업보고서' is the equivalent of the US 10-K annual report, providing a full yearly overview of company activity and financial performance. FY 2022
2023-03-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.